Serum Metabolomics Profiling to Identify Novel Biomarkers for Cyanotic Heart Disease

Serum Metabolomics Profiling to Identify Biomarkers for Unstable Angina

Although statistical evidence is clear regarding the dangerousness of unstable angina (UA), a form of coronary heart disease (CHD) characterised by high mortality and morbidity globally, it is important to recognise that diagnostic precision for the condition is unfavourable. In the present research, to gain insight into candidate biomarkers, the author draws on 1H NMR-based serum metabolic pro...

Proteomic profiling to identify prognostic biomarkers in heart failure.

BACKGROUND The ability to predict mode, as well as risk, of death in left ventricular systolic dysfunction (LVSD) is important, as the clinical and cost-effectiveness of implantable cardioverter defibrillators (ICD) therapy depends on its use in appropriately selected patient populations. The value of a proteomic approach in identifying prognostic biomarkers in LVSD is unknown. The aims of this...

Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a common malignancy that has region specific etiologies. Unfortunately, 85% of cases of HCC are diagnosed at an advanced stage. Reliable biomarkers for the early diagnosis of HCC are urgently required to reduced mortality and therapeutic expenditure. We established a non-targeted gas chromatography-time of flight-mass spectrometry (GC-TOFMS) metabolomics method...

Cyanotic congenital heart disease.

The last 15 years have witnessed a very remarkable change in the attitude of the clinician towards cyanotic congenital heart disease. It is within the memory of many that it was the custom to make a simple diagnosis of congenital heart abnormality with cyanosis, and express the opinion that little or nothing could be done about it. Then there appeared the pioneer work of Abbott and others which...

Cyanotic Congenital Heart Disease